278 related articles for article (PubMed ID: 20530278)
1. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors.
Gilligan TD; Seidenfeld J; Basch EM; Einhorn LH; Fancher T; Smith DC; Stephenson AJ; Vaughn DJ; Cosby R; Hayes DF;
J Clin Oncol; 2010 Jul; 28(20):3388-404. PubMed ID: 20530278
[TBL] [Abstract][Full Text] [Related]
2. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
Beck SD; Foster RS; Bihrle R; Donohue JP
Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
[TBL] [Abstract][Full Text] [Related]
3. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
4. Factors that influence the results of salvage surgery in patients with chemorefractory germ cell carcinomas with elevated tumor markers.
Habuchi T; Kamoto T; Hara I; Kawai K; Nakao M; Nonomura N; Kobayashi T; Ogawa O; Kamidono S; Akaza H; Okuyama A; Kato T; Miki T
Cancer; 2003 Oct; 98(8):1635-42. PubMed ID: 14534879
[TBL] [Abstract][Full Text] [Related]
5. Does serum tumor marker half-life complement pretreatment risk stratification in metastatic nonseminomatous germ cell tumors?
Gerl A; Lamerz R; Clemm C; Mann K; Hartenstein R; Wilmanns W
Clin Cancer Res; 1996 Sep; 2(9):1565-70. PubMed ID: 9816334
[TBL] [Abstract][Full Text] [Related]
6. The management of patients with clinical stage I nonseminomatous testicular tumors and persistently elevated serologic markers.
Saxman SB; Nichols CR; Foster RS; Messemer JE; Donohue JP; Einhorn LH
J Urol; 1996 Feb; 155(2):587-9. PubMed ID: 8558665
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of modeled AUC(AFP-hCG), a dynamic kinetic parameter characterizing serum tumor marker decline in patients with nonseminomatous germ cell tumor.
You B; Fronton L; Boyle H; Droz JP; Girard P; Tranchand B; Ribba B; Tod M; Chabaud S; Coquelin H; Fléchon A
Urology; 2010 Aug; 76(2):423-9.e2. PubMed ID: 20472276
[TBL] [Abstract][Full Text] [Related]
8. [Tumor markers in testicular cancer].
Mann K
Urologe A; 1990 Mar; 29(2):77-86. PubMed ID: 2158684
[TBL] [Abstract][Full Text] [Related]
9. The value of tumor markers in testicular seminomas. Results of a prospective multicenter study.
Weissbach L; Bussar-Maatz R; Mann K
Eur Urol; 1997; 32(1):16-22. PubMed ID: 9266226
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
11. Serum markers in germ cell neoplasms.
Bartlett NL; Freiha FS; Torti FM
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1245-60. PubMed ID: 1723408
[TBL] [Abstract][Full Text] [Related]
12. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
[TBL] [Abstract][Full Text] [Related]
13. Significance of elevated preoperative alpha-fetoprotein in postchemotherapy residual tumor resection for the disseminated germ cell tumors.
Kobayashi T; Kawakita M; Terachi T; Habuchi T; Ogawa O; Kamoto T
J Surg Oncol; 2006 Dec; 94(7):619-23. PubMed ID: 17111392
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of tumor markers in newly diagnosed patients with primary central nervous system germ cell tumors.
Kim A; Ji L; Balmaceda C; Diez B; Kellie SJ; Dunkel IJ; Gardner SL; Sposto R; Finlay JL
Pediatr Blood Cancer; 2008 Dec; 51(6):768-73. PubMed ID: 18802946
[TBL] [Abstract][Full Text] [Related]
15. No predictive value of beta-hCG in patients with stage I seminoma--results of a long-term follow-up study after adjuvant radiotherapy.
Bruns F; Raub M; Schaefer U; Micke O
Anticancer Res; 2005; 25(3A):1543-6. PubMed ID: 16033057
[TBL] [Abstract][Full Text] [Related]
16. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
17. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome.
Stephenson AJ; Bosl GJ; Motzer RJ; Kattan MW; Stasi J; Bajorin DF; Sheinfeld J
J Clin Oncol; 2005 Apr; 23(12):2781-8. PubMed ID: 15837993
[TBL] [Abstract][Full Text] [Related]
18. Serum tumour markers in testicular and extragonadal germ cell malignancies.
Klepp O
Scand J Clin Lab Invest Suppl; 1991; 206():28-41. PubMed ID: 1947758
[TBL] [Abstract][Full Text] [Related]
19. Tumor marker levels in post-chemotherapy cystic masses: clinical implications for patients with germ cell tumors.
Beck SD; Patel MI; Sheinfeld J
J Urol; 2004 Jan; 171(1):168-71. PubMed ID: 14665869
[TBL] [Abstract][Full Text] [Related]
20. Nonseminomatous germ cell testicular tumors clinical stage I: differentiated therapeutic approach in comparison with therapeutic approach using surveillance strategy only.
Ondrus D; Ondrusova M; Hornak M; Matoska J
Neoplasma; 2007; 54(5):437-42. PubMed ID: 17688374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]